RARE DISEASE
Thymic carcinoma
Thymic carcinoma
Thymic carcinoma
Synonyms: Malignant thymoma
Synonyms: Malignant thymoma
Synonyms: Malignant thymoma
Drug discovery
1
drug
With orphan designation
Overview
Thymic carcinoma is a rare, aggressive mediastinal malignancy arising from thymic epithelial cells, accounting for 0.07–0.38 cases per 100,000 annually [2][5][12]. It typically presents with locally invasive or metastatic disease, necessitating multimodal treatment. Histologically distinct from thymoma, it demonstrates poor differentiation and frequent TP53 mutations [5][16].
Therapies
Surgery: First-line for resectable tumors, often combined with adjuvant radiotherapy (50–75% 5-year survival post-R0 resection) [5][8]
Systemic therapy: Platinum-based regimens (e.g., carboplatin/paclitaxel) for advanced disease; emerging role for lenvatinib/pembrolizumab combinations [3][13][16]
Radiation: Used neoadjuvantly, adjuvantly, or palliatively; improves local control in incompletely resected cases [5][8]
Categories: rare neoplastic diseases
Research Papers
1,446 drug discovery papers about Thymic carcinoma, with 1 first-in-class and 1 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
1,446 drug discovery papers about Thymic carcinoma, with 1 first-in-class and 1 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-08-13 | Precision Oncology in Thymic Epithelial Tumors: Therapeutic Horizons and Implementation Barriers.
Thymic epithelial tumors (TETs), comprising thymomas and thymic carcinomas, are rare, biologically heterogeneous thoracic malignancies with limited therapeutic advances since platinum-based regimens were adopted decades ago. Recent genomic and immunophenotypic profiling has uncovered recurrent genomic alterations and high programmed death-ligand 1 (PD-L1) expression, particularly in thymic carcinoma, yet few targeted or immunotherapies have achieved regulatory approval. This mini-review synthesizes current knowledge on TET heterogeneity and the genomic landscape, evaluates the clinical evidence supporting targeted agents and immune checkpoint inhibitors, and examines emerging biomarkers, including circulating tumor DNA. We also address practical barriers to precision oncology in TETs: challenges of next-generation sequencing implementation and cost in resource-limited settings; scarcity of large, biomarker-driven trials; and safety concerns unique to TETs (immune-related toxicity). Finally, we discuss the translational hurdles for antibody-drug conjugates and cellular therapies, limited validated cell surface targets, antigen heterogeneity, and preclinical model gaps and outline strategic paths forward to enable rational, safe, and equitable precision therapeutics for TET patients.
2026-08-12 | Collision tumor of poorly differentiated thyroid carcinoma and intrathyroid thymic carcinoma arising in association with a branchial cleft-like cyst: a case report
Background Primary squamous carcinoma of the thyroid is an exceptionally rare malignancy, and its coexistence with poorly differentiated thyroid carcinoma (PDTC) is exceedingly uncommon. The pathogenesis of thyroid squamous carcinomas remains controversial, particularly when associated with congenital epithelial remnants such as branchial cleft-like cysts or thymic/ultimobranchial remnants. We report an unusual collision tumor composed of PDTC and intrathyroid thymic carcinoma (ITTC) arising in association with a longstanding cystic thyroid lesion. Case presentation A 59-year-old man initially presented with a left thyroid lesion that was interpreted as a benign branchial cleft cyst on ultrasound-guided fine-needle aspiration. After being lost to follow-up for more than four years, he re-presented with progressive enlargement of the lesion. Repeat cytology and core biopsy demonstrated a poorly differentiated carcinoma with squamous differentiation. Cross-sectional imaging revealed local invasion, retrosternal extension, and multiple bilateral pulmonary nodules suspicious for metastatic disease. Near total thyroidectomy was performed for symptomatic airway compression. Histopathological examination demonstrated two morphologically and immunophenotypically distinct malignant components: PDTC with solid, trabecular, and insular architecture, necrosis, increased mitotic activity, angioinvasion, lymphatic invasion, perineural invasion, and extrathyroidal extension; and a squamous carcinoma arising in association with a benign squamous-lined cyst. Immunohistochemically, the PDTC component expressed thyroglobulin, TTF-1, and PAX8, whereas the squamous component was positive for CK5/6, p63, and CD117 and negative for thyroid follicular markers, supporting ITTC. Outcome The final diagnosis was a collision tumor composed of PDTC and ITTC arising in association with a branchial cleft-like cyst or other embryologic cystic remnant. Although pulmonary biopsy and systemic treatment were planned, the patient developed severe bronchopneumonia and died before further staging could be completed. Conclusion This case illustrates an exceptionally rare collision tumor of the thyroid and highlights the diagnostic limitations of cytologic assessment in predominantly cystic lesions. It emphasizes the importance of repeat evaluation of enlarging cystic thyroid masses and comprehensive histopathological and immunohistochemical assessment for accurate diagnosis and appropriate clinical management.
2026-07-11 | Clinical and Immunologic Features of Primary Enteric-Type Thymic Adenocarcinomas: A Rare Variant of a Rare Cancer.
Primary thymic adenocarcinomas are a rare subtype of thymic carcinoma, which share morphologic and immunohistochemical features with gastrointestinal cancers. The immunologic features of thymic adenocarcinoma remain poorly understood, and optimal treatment strategies have not been established. In this single-institution retrospective study, we identified seven patients with enteric-type thymic adenocarcinoma. Clinical characteristics, histopathology, and molecular profiles were analyzed. Comprehensive immune profiling was conducted using peripheral blood mononuclear cells (PBMCs) and archival tumor tissue. The PBMC immune profiles were compared with those of non-adenocarcinoma thymic epithelial tumors and with samples obtained from healthy donors. Enteric-type thymic adenocarcinomas exhibit aggressive clinical behavior and respond poorly to systemic therapy, including immune checkpoint inhibitors. Genomic analyses revealed frequent TP53 mutations, a marker of poor prognosis for thymic epithelial tumors. Immune analyses in PBMCs revealed higher levels of effector T-cell subsets, including CD4+ and CD8+ T-cell subsets, and lower levels of immunosuppressive cell populations compared with other thymic epithelial tumors. Higher levels of serum analytes related to angiogenesis, cell proliferation, and growth were detected. Tumor immune profiling revealed features of an immune-desert phenotype. Enteric-type thymic adenocarcinomas are immunologically cold tumors that are enriched in peripheral immune markers reflective of cell proliferation and angiogenesis. The immunologic profile appears distinct from other thymic epithelial tumors and provides a potential explanation for the aggressive nature of this disease. If validated in other studies, these findings can potentially inform the development of optimal systemic therapies for this rare variant of thymic carcinoma.
2026-07-10 | Pathobiology of thymic epithelial tumours and the treatment strategy based on immuno-oncological characteristics: a narrative review.
Thymic epithelial tumours (TETs), including thymomas and thymic carcinomas, are relatively rare anterior mediastinal malignancies. Thymomas are well known to be associated with various autoimmune diseases, such as myasthenia gravis (MG), pure red cell aplasia, and hypogammaglobulinemia. The mainstay of treatment for all TETs is complete surgical resection, although recent advances in irradiation and anti-tumour drug therapies are increasingly indicated for advanced or recurrent disease. The pathobiology of TETs was reviewed to consider optimal treatment strategies based on their immuno-oncological characteristics. A comprehensive literature search was conducted using PubMed, focusing on the biology and treatment of TETs, along with integration of our original research data. Pathobiology is different between thymoma and thymic carcinoma. Incomplete T cell development is observed in thymoma, which may affect patient autoimmunity. Type AB, B1, and B2 thymomas harbour abundant immature T cells, which cannot act as effector T cells in treatment using immune checkpoint inhibitors (ICIs). Neoplastic thymic epithelial cells (TECs) express programmed cell death-ligand 1 (PD-L1) at varying levels, and frequent genetic aberrations are observed according to the World Health Organization (WHO) classification. Germinal centre formation in the surrounding thymus may have a clinical role in thymoma-associated MG. Regarding treatment strategies, radical minimally invasive thymectomy using robotic technology is now available for MG. Effective molecular-targeted and ICI therapies have recently been introduced, and further novel targeted therapies are currently under development. WHO histological subtypes and inflammatory biomarkers are practically useful for determining the treatment strategy. A fundamental understanding of pathobiology and immuno-oncology is crucial for the appropriate management of TETs.
2026-07-10 | Systemic therapy for advanced thymic epithelial tumors: a narrative review of current evidence and perspectives.
Thymic epithelial tumors (TETs), including thymoma and thymic carcinoma, are rare tumors. Although systemic therapy is commonly used for unresectable advanced or recurrent TETs, establishing robust evidence remains challenging. This narrative review summarizes current evidence and incorporates the latest clinical trial data, reporting outcomes separately for thymoma and thymic carcinoma whenever possible. We also highlight practical considerations relevant to clinical practice, including dosing strategies and toxicity management. We searched PubMed and Google Scholar for prospective and retrospective original studies, meta-analyses, review articles, and case studies published up to November 2025 using terms including "thymoma", "thymic carcinoma", "thymic cancer", "thymic tumors", "thymic epithelial tumors", "chemotherapy", "systemic treatment", "immunotherapy", and "targeted therapy". Ongoing trials were identified via ClinicalTrials.gov and the Japan Registry of Clinical Trials. Retrospective studies enrolling fewer than 15 participants were excluded. Systemic therapy for advanced TETs continues to include cytotoxic chemotherapy as a major component. In selected settings, particularly in thymic carcinoma, targeted therapy and immune checkpoint inhibitors (ICIs) represent additional active options. Emerging trials suggest that combination strategies may enhance efficacy. Novel drugs, including bispecific antibodies and antibody-drug conjugates, are being evaluated in ongoing phase II trials. Despite the rarity of TETs, systemic treatment options have gradually expanded through the accumulation of evidence from small phase II studies. Future advances will require collaborative prospective trials to validate predictive biomarkers and support biomarker-enriched trial designs.
2026-08-13 | Precision Oncology in Thymic Epithelial Tumors: Therapeutic Horizons and Implementation Barriers.
Thymic epithelial tumors (TETs), comprising thymomas and thymic carcinomas, are rare, biologically heterogeneous thoracic malignancies with limited therapeutic advances since platinum-based regimens were adopted decades ago. Recent genomic and immunophenotypic profiling has uncovered recurrent genomic alterations and high programmed death-ligand 1 (PD-L1) expression, particularly in thymic carcinoma, yet few targeted or immunotherapies have achieved regulatory approval. This mini-review synthesizes current knowledge on TET heterogeneity and the genomic landscape, evaluates the clinical evidence supporting targeted agents and immune checkpoint inhibitors, and examines emerging biomarkers, including circulating tumor DNA. We also address practical barriers to precision oncology in TETs: challenges of next-generation sequencing implementation and cost in resource-limited settings; scarcity of large, biomarker-driven trials; and safety concerns unique to TETs (immune-related toxicity). Finally, we discuss the translational hurdles for antibody-drug conjugates and cellular therapies, limited validated cell surface targets, antigen heterogeneity, and preclinical model gaps and outline strategic paths forward to enable rational, safe, and equitable precision therapeutics for TET patients.
2026-08-12 | Collision tumor of poorly differentiated thyroid carcinoma and intrathyroid thymic carcinoma arising in association with a branchial cleft-like cyst: a case report
Background Primary squamous carcinoma of the thyroid is an exceptionally rare malignancy, and its coexistence with poorly differentiated thyroid carcinoma (PDTC) is exceedingly uncommon. The pathogenesis of thyroid squamous carcinomas remains controversial, particularly when associated with congenital epithelial remnants such as branchial cleft-like cysts or thymic/ultimobranchial remnants. We report an unusual collision tumor composed of PDTC and intrathyroid thymic carcinoma (ITTC) arising in association with a longstanding cystic thyroid lesion. Case presentation A 59-year-old man initially presented with a left thyroid lesion that was interpreted as a benign branchial cleft cyst on ultrasound-guided fine-needle aspiration. After being lost to follow-up for more than four years, he re-presented with progressive enlargement of the lesion. Repeat cytology and core biopsy demonstrated a poorly differentiated carcinoma with squamous differentiation. Cross-sectional imaging revealed local invasion, retrosternal extension, and multiple bilateral pulmonary nodules suspicious for metastatic disease. Near total thyroidectomy was performed for symptomatic airway compression. Histopathological examination demonstrated two morphologically and immunophenotypically distinct malignant components: PDTC with solid, trabecular, and insular architecture, necrosis, increased mitotic activity, angioinvasion, lymphatic invasion, perineural invasion, and extrathyroidal extension; and a squamous carcinoma arising in association with a benign squamous-lined cyst. Immunohistochemically, the PDTC component expressed thyroglobulin, TTF-1, and PAX8, whereas the squamous component was positive for CK5/6, p63, and CD117 and negative for thyroid follicular markers, supporting ITTC. Outcome The final diagnosis was a collision tumor composed of PDTC and ITTC arising in association with a branchial cleft-like cyst or other embryologic cystic remnant. Although pulmonary biopsy and systemic treatment were planned, the patient developed severe bronchopneumonia and died before further staging could be completed. Conclusion This case illustrates an exceptionally rare collision tumor of the thyroid and highlights the diagnostic limitations of cytologic assessment in predominantly cystic lesions. It emphasizes the importance of repeat evaluation of enlarging cystic thyroid masses and comprehensive histopathological and immunohistochemical assessment for accurate diagnosis and appropriate clinical management.
2026-07-11 | Clinical and Immunologic Features of Primary Enteric-Type Thymic Adenocarcinomas: A Rare Variant of a Rare Cancer.
Primary thymic adenocarcinomas are a rare subtype of thymic carcinoma, which share morphologic and immunohistochemical features with gastrointestinal cancers. The immunologic features of thymic adenocarcinoma remain poorly understood, and optimal treatment strategies have not been established. In this single-institution retrospective study, we identified seven patients with enteric-type thymic adenocarcinoma. Clinical characteristics, histopathology, and molecular profiles were analyzed. Comprehensive immune profiling was conducted using peripheral blood mononuclear cells (PBMCs) and archival tumor tissue. The PBMC immune profiles were compared with those of non-adenocarcinoma thymic epithelial tumors and with samples obtained from healthy donors. Enteric-type thymic adenocarcinomas exhibit aggressive clinical behavior and respond poorly to systemic therapy, including immune checkpoint inhibitors. Genomic analyses revealed frequent TP53 mutations, a marker of poor prognosis for thymic epithelial tumors. Immune analyses in PBMCs revealed higher levels of effector T-cell subsets, including CD4+ and CD8+ T-cell subsets, and lower levels of immunosuppressive cell populations compared with other thymic epithelial tumors. Higher levels of serum analytes related to angiogenesis, cell proliferation, and growth were detected. Tumor immune profiling revealed features of an immune-desert phenotype. Enteric-type thymic adenocarcinomas are immunologically cold tumors that are enriched in peripheral immune markers reflective of cell proliferation and angiogenesis. The immunologic profile appears distinct from other thymic epithelial tumors and provides a potential explanation for the aggressive nature of this disease. If validated in other studies, these findings can potentially inform the development of optimal systemic therapies for this rare variant of thymic carcinoma.
2026-07-10 | Pathobiology of thymic epithelial tumours and the treatment strategy based on immuno-oncological characteristics: a narrative review.
Thymic epithelial tumours (TETs), including thymomas and thymic carcinomas, are relatively rare anterior mediastinal malignancies. Thymomas are well known to be associated with various autoimmune diseases, such as myasthenia gravis (MG), pure red cell aplasia, and hypogammaglobulinemia. The mainstay of treatment for all TETs is complete surgical resection, although recent advances in irradiation and anti-tumour drug therapies are increasingly indicated for advanced or recurrent disease. The pathobiology of TETs was reviewed to consider optimal treatment strategies based on their immuno-oncological characteristics. A comprehensive literature search was conducted using PubMed, focusing on the biology and treatment of TETs, along with integration of our original research data. Pathobiology is different between thymoma and thymic carcinoma. Incomplete T cell development is observed in thymoma, which may affect patient autoimmunity. Type AB, B1, and B2 thymomas harbour abundant immature T cells, which cannot act as effector T cells in treatment using immune checkpoint inhibitors (ICIs). Neoplastic thymic epithelial cells (TECs) express programmed cell death-ligand 1 (PD-L1) at varying levels, and frequent genetic aberrations are observed according to the World Health Organization (WHO) classification. Germinal centre formation in the surrounding thymus may have a clinical role in thymoma-associated MG. Regarding treatment strategies, radical minimally invasive thymectomy using robotic technology is now available for MG. Effective molecular-targeted and ICI therapies have recently been introduced, and further novel targeted therapies are currently under development. WHO histological subtypes and inflammatory biomarkers are practically useful for determining the treatment strategy. A fundamental understanding of pathobiology and immuno-oncology is crucial for the appropriate management of TETs.
2026-07-10 | Systemic therapy for advanced thymic epithelial tumors: a narrative review of current evidence and perspectives.
Thymic epithelial tumors (TETs), including thymoma and thymic carcinoma, are rare tumors. Although systemic therapy is commonly used for unresectable advanced or recurrent TETs, establishing robust evidence remains challenging. This narrative review summarizes current evidence and incorporates the latest clinical trial data, reporting outcomes separately for thymoma and thymic carcinoma whenever possible. We also highlight practical considerations relevant to clinical practice, including dosing strategies and toxicity management. We searched PubMed and Google Scholar for prospective and retrospective original studies, meta-analyses, review articles, and case studies published up to November 2025 using terms including "thymoma", "thymic carcinoma", "thymic cancer", "thymic tumors", "thymic epithelial tumors", "chemotherapy", "systemic treatment", "immunotherapy", and "targeted therapy". Ongoing trials were identified via ClinicalTrials.gov and the Japan Registry of Clinical Trials. Retrospective studies enrolling fewer than 15 participants were excluded. Systemic therapy for advanced TETs continues to include cytotoxic chemotherapy as a major component. In selected settings, particularly in thymic carcinoma, targeted therapy and immune checkpoint inhibitors (ICIs) represent additional active options. Emerging trials suggest that combination strategies may enhance efficacy. Novel drugs, including bispecific antibodies and antibody-drug conjugates, are being evaluated in ongoing phase II trials. Despite the rarity of TETs, systemic treatment options have gradually expanded through the accumulation of evidence from small phase II studies. Future advances will require collaborative prospective trials to validate predictive biomarkers and support biomarker-enriched trial designs.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
1 orphan drug designation for Thymic carcinoma.
1 orphan drug designation for Thymic carcinoma.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
(1R,2R)-1,2-cyclohexane-diaminepyrophosphato-platinum(II) | small molecules | FDA | 2018-10-25 | — | Promontory Therapeutics, Inc. |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.